Anti SARS-CoV-2(2019-nCoV) Spike glycoprotein monoclonal antibody
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant SARS-CoV-2(2019-nCoV) Spike glycoprotein.
Recognizes SARS-CoV-2 Spike glycoprotein
Spike glycoprotein,S glycoprotei,E2,Peplomer protein,Spike protein S1,Spike protein S2,Spike protein S2',S
Mediates fusion of the virion and cellular membranes by acting as a class I viral fusion protein. Under the current model, the protein has at least three conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During viral and target cell membrane fusion, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes.
Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2)
Recombinant SARS-CoV-2 (2019-nCoV) Spike protein fragment 1[679-833]
Use a manual defrost freezer and avoid repeated freeze thaw cycles.
Store at 2 to 8 °C for one week .
Store at -20 to -80 °C for twelve months from the date of receipt.
PBS, pH7.4, containing 0.05% proclin300, 50% glycerol.